Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver

  • 0 views
  • 20 Oct, 2022
  • 4 locations
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus Sunitinib or PRRT (CABOTEM)

The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy

  • 0 views
  • 20 Oct, 2021
  • 1 location
A Single-arm Phase II Study of Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Who Failed a Platinum-based Chemotherapy

To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in patients with recurrent/metastatic esophageal squamous cell carcinoma.

atezolizumab
g-csf
neutrophil count
platinum-based chemotherapy
immunomodulator
  • 0 views
  • 18 Oct, 2022
  • 1 location
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients

  • 0 views
  • 22 Oct, 2022
  • 1 location
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer (IREKI)

The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their

dialysis
renal failure
vascular endothelial growth factor
cancer
  • 0 views
  • 04 Oct, 2022
  • 5 locations
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK)

The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are

targeted therapy
nephrectomy
neutrophil count
cancer
cabozantinib
  • 42 views
  • 22 Apr, 2022
  • 2 locations
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic

  • 0 views
  • 04 Oct, 2022
  • 5 locations
TARGETed Therapy Drug MONITOring in DIGestive Oncology (TARGETMONITO)

Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of determine the optimal …

cabozantinib
measurable disease
cancer
  • 0 views
  • 07 Oct, 2022
  • 1 location
Phase II Trial of Regorafenib in Patients With Unresectable Hepatocellular Carcinoma After Progression on First Line Atezolizumab Plus Bevacizumab (REGONEXT Trial) (HCC)

To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination

renal function
neutrophil count
  • 0 views
  • 16 Oct, 2022
  • 2 locations
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker

alveolar soft part sarcoma
soft tissue sarcoma
advanced sarcoma
cancer
liposarcoma
  • 0 views
  • 04 Jun, 2022
  • 1 location